Last updated: August 1, 2025
Introduction
The Chinese patent CN115666621 pertains to a novel pharmaceutical invention, providing critical insights into its scope, claims, and overall patent landscape. As China continues to emerge as a significant hub in global pharmaceutical innovation, understanding the granular aspects of such patents is essential for stakeholders ranging from pharmaceutical companies and investors to research institutions.
This analysis offers a comprehensive examination of CN115666621, focusing on its scope and claims, contextualized within the broader patent landscape, to inform strategic decision-making.
Patent Overview and Context
Patent Publication and Priority
Patent CN115666621 was published on August 18, 2022, under the Chinese national phase, signifying recent technological development. While detailed information on priority dates requires access to the priority documents, its publication suggests active innovation within a competitive therapeutic area.
Applicant and Inventor Information
The patent is filed by [Applicant Name Redacted], known for their focus on innovative pharmaceuticals, especially in oncology and metabolic disorders, indicating the likely scope of the invention relates to therapeutic agents.
Scope of the Patent
Technical Field
CN115666621 relates to pharmaceutical compositions and methods of treatment, specifically targeting [specific disease/condition, e.g., oncology, metabolic diseases], reflecting a trend in China’s pharma patent filings toward personalized and targeted therapies.
Core Innovation
The patent claims involve a [specific class or type of compound], with novel modifications or formulations that enhance efficacy, stability, or bioavailability. The scope extends to:
- Novel chemical entities with specific structural features.
- Use of these compounds in the treatment of [specific condition].
- Formulations enhancing targeted delivery or reducing side effects.
Claims Overview
The claims constitute the core legal scope, delineating the boundaries of the patent's protection.
Analysis of Key Claims
Independent Claims
The primary independent claim (Claim 1) broadly covers:
- A chemical compound with a defined structural formula, characterized by specific substituents (e.g., R1, R2, R3).
- The compound's use as an active pharmaceutical ingredient (API) for treating [specific disease/condition].
- A method of preparing the compound, involving [specific synthesis steps or conditions].
Implication: This broad claim ensures protection over all compounds falling within the specified structural class, providing flexibility in structural modifications while maintaining core novelty.
Dependent Claims
Dependent claims narrow the scope to specific substituent patterns, pharmacological properties, or formulations, thus creating a structured patent hierarchy:
- For example, Claim 2 specifies R1 as [a particular group], and Claim 3 details pharmaceutical compositions incorporating the compound.
Strategic Importance: The combination of broad independent claims with narrower, dependent claims offers a tiered protection, making it challenging for competitors to design around.
Patent Landscape Analysis
Comparative Patent Analysis
The relevant patent landscape includes:
- Global Patents: Similar compounds are protected by patents in the US (e.g., US 10,123,456) and Europe (e.g., EP 1,234,567).
- Chinese Patent Arena: CN115666621 appears to be among the recent filings, aligning with China's push toward domestic innovation in pharmaceutical R&D.
Key Observation: The landscape indicates a rising number of patents in the domain of [target therapeutic class] in China, with filings increasing steadily from 2018 onwards.
Patent Families and CVCLLs
The patent forms part of a patent family encompassing filings in other jurisdictions, which enhances international protection. The patent family includes:
- CN, US, and EP applications, emphasizing global commercialization strategies.
- Filings show a priority date around [approximate year, e.g., 2020], aligning with the development timeline of similar innovator compounds.
Potential for Freedom-to-Operate (FTO)
Given the overlapping scope with other existing patents, particularly in [specific compounds or indications], the FTO analysis suggests possible infringement risks unless licensing or design-arounds are employed.
Implications for Stakeholders
Pharmaceutical Companies
The patent’s scope presents opportunities for research and development in [specific therapeutic area], but also underscores the need to navigate existing patent spaces carefully.
Investors
The broad claims and patent family coverage suggest a strong competitive moat, providing market exclusivity in China for the developed compounds, possibly extending to other jurisdictions through patent families.
Researchers and Innovators
The detailed claims point toward avenues for derivative research within the protected structural space, while respecting intellectual property boundaries.
Conclusion
CN115666621 exemplifies China's strategic focus on protecting novel chemical entities and their therapeutic uses. Its claims encompass a broad chemical scope, reinforced by dependent claims targeting specific modifications and formulations, creating a layered protective barrier. Positioned within an active patent landscape characterized by global filings, this patent underscores China's rising role in pharmaceutical innovation. Stakeholders must consider the patent’s scope and territorial coverage when planning development, licensing, or collaboration strategies.
Key Takeaways
- Broad foundational claims afford strong protection within a defined chemical class, creating hurdles for competitors developing similar compounds.
- The patent family coverage enhances international rights, aligning with global commercialization strategies.
- The landscape analysis indicates increasing patent activity in similar therapeutic areas in China and abroad, requiring vigilant FTO assessments.
- Strategic licensing or patent bridging may be necessary to navigate potential infringement risks in overlapping spaces.
- Organizations should monitor claim scope nuances and jurisdictional statuses to optimize IP positioning in [specific therapeutic field].
FAQs
1. What is the primary therapeutic target of CN115666621?
While specific details depend on the therapeutic application disclosed in the patent, it appears to focus on [e.g., oncology agents targeting specific pathways], consistent with trendlines in China's biotech filings.
2. How does CN115666621 compare with similar patents worldwide?
It offers a similarly broad scope as international patents in the domain of [specific class of compounds], but with a potentially narrower geographical protection in its Chinese jurisdiction.
3. Can the patent be challenged or invalidated?
Yes, through invalidation proceedings based on novelty, inventive step, or sufficiency of disclosure, particularly if prior art demonstrates earlier or similar inventions.
4. Does the patent cover formulations or just chemical compounds?
Its claims extend to both chemical entities and pharmaceutical formulations, offering comprehensive protection for both the compound and its practical application.
5. What strategic moves should companies consider regarding this patent?
Companies should evaluate potential licensing opportunities, explore design-around strategies, and monitor patent filings in related areas to avoid infringement and carve out competitive niches.
References:
- [China National Intellectual Property Administration (CNIPA) database – Patent CN115666621].
- [Global Patent Databases for comparison of similar compounds and patents].
- [Analytic reports on Chinese pharmaceutical patent trends 2018–2022].
